



**Suitability Petition
Completeness Assessment Correspondence**

Epic Pharma, LLC
U.S. Agent for Humanwell Pharmaceutical US, Inc.
227-15 North Conduit Avenue
Laurelton, NY 11413
Attn: Pei Zhang

Sent via email to: RADept@epic-pharma.com

Docket No. FDA-2024-P-3090

Dear Pei Zhang:

This is in reference to your petition received on June 28, 2024, by the U.S. Food and Drug Administration (FDA or Agency), requesting permission, in accordance with 21 C.F.R. §314.93(b), to submit an Abbreviated New Drug Application (ANDA) for the following drug product: Eslicarbazepine Acetate Oral Suspension, 50 mg/mL. The petition was examined for initial completeness (i.e. Completeness Assessment) under CFR 10.30 and the Agency has made a threshold determination that the petition is complete.

This petition is subject to the provisions of the Generic Drugs User Fee Amendments of 2022 (GDUFA III) whereby any suitability petitions submitted in FY 2024-2027 will receive a goal date of 6 months after the completeness assessment. The GDUFA goal date for review of this petition is January 10, 2025.

If you have any questions, contact ANDAFiling@fda.hhs.gov.

A copy of this letter will be placed on public display in the Dockets Management



Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely,

{See appended electronic signature page}

Diana Guon, Pharm.D., BCPS
Pharmacist
Division of Filing Review
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Diana
Guon

Digitally signed by Diana Guon

Date: 7/10/2024 09:15:06AM

GUID: 5bc8dc49000a17d3803dd3b2e8a20cdb